Table 4.
Estimated HR for independent factors associated with SPK transplant outcomes in type 2 diabetic recipients and comparison to HR of similar covariates in recipients with T1DM diagnosis
| Covariate | Reference | Levels | T2DM |
T1DM |
||
|---|---|---|---|---|---|---|
| Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
|||||
| Model 1 | Model 2a | |||||
| Patient death | ||||||
| recipient age | ≤45 years | >45 years | 2.16 (1.28 to 3.62) | 2.13 (1.26 to 3.59) | 2.16 (1.27 to 3.64) | 1.29 (1.09 to 1.52) |
| pretransplant dialysis | Pre-emptive | >1 year | 2.57 (1.11 to 5.97) | 2.58 (1.11 to 6.00) | 2.60 (1.12 to 6.06) | 1.59 (1.21 to 1.89) |
| calcineurin inhibitor | No drug | CsA | 0.54 (0.19 to 1.51) | 0.66 (0.23 to 1.85) | 0.65 (0.23 to 1.84) | 0.47 (0.34 to 0.65) |
| Tac | 0.30 (0.17 to 0.53) | 0.37 (0.19 to 0.69) | 0.36 (0.19 to 0.69) | 0.36 (0.28 to 0.46) | ||
| steroid | No drug | Yes | 0.32 (0.16 to 0.62) | 0.41 (0.20 to 0.84) | 0.44 (0.20 to 0.99) | 0.84 (0.58 to 1.21) |
| Overall kidney graft loss | ||||||
| pretransplant dialysis | Pre-emptive | >1 year | 2.08 (1.16 to 3.72) | 2.48 (1.38 to 4.47) | 2.44 (1.35 to 4.39) | 1.26 (1.04 to 1.45) |
| steroid | No drug | Yes | 0.31 (0.19 to 0.51) | 0.38 (0.21 to 0.67) | 0.29 (1.16 to 0.56) | 0.66 (0.49 to 0.89) |
| calcineurin inhibitor | No drug | CsA | 0.50 (0.21 to 1.16) | 0.52 (0.22 to 1.24) | 0.69 (0.27 to 1.70) | 0.50 (0.38 to 0.66) |
| Tac | 0.35 (0.22 to 0.55) | 0.43 (0.26 to 0.71) | 0.47 (0.28 to 0.79) | 0.42 (0.35 to 0.52) | ||
| induction | No drug | Alem | 1.19 (0.97 to 4.00) | 2.10 (1.01 to 4.35) | 0.53 (0.07 to 4.51) | 0.47 (0.24 to 0.91) |
| Thym | 0.77 (0.51 to 1.15) | 0.88 (0.57 to 1.34) | 0.21 (0.02 to 1.74) | 0.48 (0.26 to 0.89) | ||
| IL2-RA | 0.51 (0.25 to 1.04) | 0.60 (0.30 to 1.24) | 0.14 (0.01 to 1.27) | 0.44 (0.23 to 0.84) | ||
| Others | 0.97 (0.030 to 3.12) | 1.39 (0.43 to 4.51) | 0.31 (0.28 to 3.53) | 0.52 (0.26 to 1.02) | ||
| Multiple | 1.13 (0.48 to 2.63) | 1.18 (0.49 to 2.81) | 0.27 (0.03 to 3.53) | 0.58 (0.30 to 1.14) | ||
| Overall pancreas graft loss | ||||||
| BMI | 18.5 to 25 | <18.5 | 1.26 (0.45 to 3.48) | 1.11 (0.39 to 3.09) | 1.08 (0.38 to 3.01) | 0.94 (0.67 to 1.31) |
| 25 to 30 | 1.49 (1.02 to 2.16) | 1.58 (1.08 to 2.29) | 1.69 (1.09 to 2.33) | 0.96 (0.85 to 1.08) | ||
| >30 | 1.81 (1.18 to 2.79) | 1.67 (1.08 to 2.59) | 1.71 (1.10 to 2.64) | 1.27 (1.07 to 1.49) | ||
| steroid | No drug | Yes | 0.41 (0.25 to 0.68) | 0.53 (0.31 to 0.91) | 0.59 (0.33 to 1.05) | 0.92 (0.72 to 1.19) |
| calcineurin inhibitor | No drug | CsA | 0.71 (0.35 to 1.44) | 0.81 (0.39 to 1.66) | 0.81 (0.39 to 1.66) | 0.54 (0.42 to 0.67) |
| Tac | 0.37 (0.24 to 0.57) | 0.42 (0.27 to 0.66) | 0.42 (0.27 to 0.66) | 0.44 (0.37 to 0.53) | ||
Results were presented as HRs with 95% CI. CsA, cyclosporine A, Tac, tacrolimus; Alem, alemtuzumab; thym, thymoglobulin; Others, ALG/OKT3.
a
Model 2 included a covariate to account for interaction between use of induction and steroid.